## Aminah Jatoi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2912763/publications.pdf

Version: 2024-02-01

300 papers

13,403 citations

66234 42 h-index 109 g-index

304 all docs

304 docs citations

304 times ranked 15052 citing authors

#	Article	IF	Citations
1	Definition and classification of cancer cachexia: an international consensus. Lancet Oncology, The, 2011, 12, 489-495.	5.1	4,015
2	Cachexia: A new definition. Clinical Nutrition, 2008, 27, 793-799.	2.3	1,906
3	Sarcopenia: A Time for Action. An SCWD Position Paper. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 956-961.	2.9	410
4	Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology, 2002, 20, 567-573.	0.8	279
5	A Phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer, 2003, 97, 1442-1446.	2.0	274
6	An Eicosapentaenoic Acid Supplement Versus Megestrol Acetate Versus Both for Patients With Cancer-Associated Wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada Collaborative Effort. Journal of Clinical Oncology, 2004, 22, 2469-2476.	0.8	256
7	Complete Pathologic Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is Associated With Enhanced Survival. Annals of Thoracic Surgery, 2009, 87, 392-399.	0.7	240
8	Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. Ca-A Cancer Journal for Clinicians, 2021, 71, 78-92.	157.7	230
9	The Outcome of Combined-Modality Therapy for Stage III Non–Small-Cell Lung Cancer in the Elderly. Journal of Clinical Oncology, 2003, 21, 3201-3206.	0.8	223
10	Tetracycline to prevent epidermal growth factor receptor inhibitorâ€induced skin rashes. Cancer, 2008, 113, 847-853.	2.0	167
11	A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer, 2010, 68, 234-239.	0.9	167
12	Current Management Strategies for Ovarian Cancer. Mayo Clinic Proceedings, 2007, 82, 751-770.	1.4	156
13	Cachexia and Sarcopenia in Older Adults with Cancer: A Comprehensive Review. Cancers, 2019, 11, 1861.	1.7	132
14	Current Management Strategies for Ovarian Cancer. Mayo Clinic Proceedings, 2007, 82, 751-770.	1.4	127
15	A placeboâ€controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome. Cancer, 2007, 110, 1396-1403.	2.0	120
16	Should Elderly Non–Small-Cell Lung Cancer Patients Be Offered Elderly-Specific Trials? Results of a Pooled Analysis From the North Central Cancer Treatment Group. Journal of Clinical Oncology, 2005, 23, 9113-9119.	0.8	116
17	Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition?. Cancer, 2005, 103, 863-868.	2.0	106
18	Search for Evidence-Based Approaches for the Prevention and Palliation of Hand–Foot Skin Reaction (HFSR) Caused by the Multikinase Inhibitors (MKIs). Oncologist, 2009, 14, 291-302.	1.9	103

#	Article	IF	Citations
19	Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. Gynecologic Oncology, 2016, 142, 311-316.	0.6	103
20	Does Zinc Sulfate Prevent Therapy-Induced Taste Alterations in Head and Neck Cancer Patients? Results of Phase III Double-Blind, Placebo-Controlled Trial from the North Central Cancer Treatment Group (N01C4). International Journal of Radiation Oncology Biology Physics, 2007, 67, 1318-1322.	0.4	100
21	ZIP4 Promotes Muscle Wasting and Cachexia in Mice With Orthotopic Pancreatic Tumors by Stimulating RAB27B-Regulated Release of Extracellular Vesicles From Cancer Cells. Gastroenterology, 2019, 156, 722-734.e6.	0.6	82
22	Oral Cancer Chemotherapy: The Critical Interplay Between Patient Education and Patient Safety. Current Oncology Reports, 2010, 12, 247-252.	1.8	73
23	A Tomato-Based, Lycopene-Containing Intervention for Androgen-Independent Prostate Cancer: Results of a Phase II Study from The North Central Cancer Treatment Group. Urology, 2007, 69, 289-294.	0.5	71
24	Does Marital Status Impact Survival and Quality of Life in Patients with Nonâ€6mall Cell Lung Cancer? Observations from the Mayo Clinic Lung Cancer Cohort. Oncologist, 2007, 12, 1456-1463.	1.9	67
25	Motivational readiness for physical activity and quality of life in long-term lung cancer survivors. Lung Cancer, 2008, 61, 117-122.	0.9	67
26	Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147. Oncology, 2009, 77, 120-123.	0.9	67
27	Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer. Journal of the American Geriatrics Society, 2019, 67, 920-927.	1.3	67
28	Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. Journal of Clinical Oncology, 2017, 35, 421-431.	0.8	65
29	Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. Oncologist, 2016, 21, 1483-1491.	1.9	64
30	Effect of cigarette smoking on quality of life in small cell lung cancer patients. European Journal of Cancer, 2012, 48, 1593-1601.	1.3	61
31	Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2,388 health care providers. Supportive Care in Cancer, 2015, 23, 151-157.	1.0	60
32	Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. Clinical Colorectal Cancer, 2018, 17, 85-96.	1.0	60
33	Fatigue, Dyspnea, and Cough Comprise a Persistent Symptom Cluster Up to Five Years After Diagnosis with Lung Cancer. Journal of Pain and Symptom Management, 2011, 42, 202-212.	0.6	59
34	Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. Journal of Clinical Oncology, 2019, 37, 2338-2348.	0.8	56
35	The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer, 2007, 110, 363-368.	2.0	54
36	Quantification of Somatic Chromosomal Rearrangements in Circulating Cell-Free DNA from Ovarian Cancers. Scientific Reports, 2016, 6, 29831.	1.6	53

#	Article	IF	CITATIONS
37	Prevalence and Survival Impact of Pretreatment Cancer-Associated Weight Loss: A Tool for Guiding Early Palliative Care. Journal of Oncology Practice, 2018, 14, e238-e250.	2.5	53
38	Does Sunscreen Prevent Epidermal Growth Factor Receptor (EGFR) Inhibitor–Induced Rash? Results of a Placebo-Controlled Trial from the North Central Cancer Treatment Group (N05C4). Oncologist, 2010, 15, 1016-1022.	1.9	52
39	Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary) Tj ETQq1 1 0.784	-311 <b>4</b> rgBT	/ <b>©</b> verlock 10
40	On Appetite and Its Loss. Journal of Clinical Oncology, 2000, 18, 2930-2932.	0.8	50
41	Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure?. Annals of Thoracic Surgery, 2001, 72, 348-351.	0.7	48
42	Gaps in nutritional research among older adults with cancer. Journal of Geriatric Oncology, 2016, 7, 281-292.	0.5	47
43	Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. Nature Communications, 2020, 11, 5173.	5.8	46
44	EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review. Genes and Cancer, 2017, 8, 589-599.	0.6	45
45	Non–Small-Cell Lung Cancer in Elderly Patients: A Discussion of Treatment Options. Journal of Clinical Oncology, 2014, 32, 2562-2569.	0.8	44
46	Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: A pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. International Journal of Oncology, 2010, 36, 601-6.	1.4	43
47	Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907. Journal of Clinical Oncology, 2016, 34, 699-705.	0.8	42
48	Conversations About Financial Issues in Routine Oncology Practices: A Multicenter Study. Journal of Oncology Practice, 2019, 15, e690-e703.	2.5	42
49	Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity. Lung Cancer, 2004, 43, 345-353.	0.9	41
50	A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341,) Tj ETQq0 0 0 r Cancer Chemotherapy and Pharmacology, 2006, 59, 207-215.	rgBT /Over 1.1	lock 10 Tf 5
51	Growth differentiating factor-15 (GDF-15): A potential biomarker and therapeutic target for cancer-associated weight loss. Oncology Letters, 2016, 12, 4219-4223.	0.8	41
52	Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B). Journal of Thoracic Oncology, 2008, 3, 516-520.	0.5	36
53	Is voluntary vitamin and mineral supplementation associated with better outcome in non-small cell lung cancer patients?. Lung Cancer, 2005, 49, 77-84.	0.9	35
54	Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. Gynecologic Oncology, 2017, 146, 64-68.	0.6	35

#	Article	IF	CITATIONS
55	Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. ESMO Open, 2020, 5, e000926.	2.0	35
56	On Appetite and Its Loss. Journal of Clinical Oncology, 2003, 21, 79s-81.	0.8	35
57	A Phase II Trial of Docetaxel and CPT-11 in Patients with Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia. International Journal of Gastrointestinal Cancer, 2003, 32, 115-124.	0.4	34
58	Do Patients Die from Rashes from Epidermal Growth Factor Receptor Inhibitors? A Systematic Review to Help Counsel Patients About Holding Therapy. Oncologist, 2008, 13, 1201-1204.	1.9	34
59	Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. The Journal of Supportive Oncology, 2003, 1, 274-8.	2.3	34
60	Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: A histologic dichotomy. Gynecologic Oncology, 2014, 132, 578-584.	0.6	33
61	Characterizing cancer cachexia in the geriatric oncology population. Journal of Geriatric Oncology, 2019, 10, 415-419.	0.5	33
62	Hydronephrosis in patients with cervical cancer: an assessment of morbidity and survival. Supportive Care in Cancer, 2015, 23, 1303-1309.	1.0	32
63	North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogeneticâ€based dosing of irinotecan, oxaliplatin, and capecitabine as firstâ€ine therapy for patients with advanced small bowel adenocarcinoma. Cancer, 2017, 123, 3494-3501.	2.0	32
64	A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. Supportive Care in Cancer, 2004, 12, 859-863.	1.0	31
65	Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs. Supportive Care in Cancer, 2005, 13, 66-69.	1.0	31
66	A Mixed-Methods Feasibility Trial of Protein Kinase C lota Inhibition with Auranofin in Asymptomatic Ovarian Cancer Patients. Oncology, 2015, 88, 208-213.	0.9	30
67	Menopausal hormone therapy in cancer survivors: A narrative review of the literature. Maturitas, 2016, 92, 86-96.	1.0	30
68	Acquisition of sexual orientation and gender identity data among NCI Community Oncology Research Program practice groups. Cancer, 2019, 125, 1313-1318.	2.0	30
69	Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia. Cancer, 2001, 92, 629-633.	2.0	29
70	Weekly Carboplatin and Paclitaxel in Elderly Non–Small-Cell Lung Cancer Patients (≥65 Years of Age). American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 441-447.	0.6	29
71	Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group. Supportive Care in Cancer, 2005, 13, 381-386.	1.0	29
72	A hunger for hunger: a review of palliative therapies for cancer-associated anorexia. Annals of Palliative Medicine, 2019, 8, 50-58.	0.5	29

#	Article	IF	Citations
73	Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. Supportive Care in Cancer, 2002, 10, 71-75.	1.0	28
74	The cancer anorexia/weight loss syndrome: Therapeutic challenges. Current Oncology Reports, 2005, 7, 271-276.	1.8	28
75	Pharmacological options for advanced cancer patients with loss of appetite and weight. Expert Opinion on Pharmacotherapy, 2007, 8, 1085-1090.	0.9	27
76	Weight loss in patients with advanced cancer: effects, causes, and potential management. Current Opinion in Supportive and Palliative Care, 2008, 2, 45-48.	0.5	26
77	A Phase II Study of Topical Ceramides for Cutaneous Breast Cancer. Breast Cancer Research and Treatment, 2003, 80, 99-104.	1.1	25
78	Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients. Clinical Nutrition, 2006, 25, 711-715.	2.3	25
79	Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation for Locally Advanced Esophageal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 507-513.	0.6	25
80	The prognostic effect of increased resting energy expenditure prior to treatment for lung cancer. Lung Cancer, 1999, 23, 153-158.	0.9	24
81	Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer. The Journal of Supportive Oncology, 2004, 2, 323-34; discussion 334-7.	2.3	24
82	Does dietary counseling improve quality of life in cancer patients? A systematic review and meta-analysis. The Journal of Supportive Oncology, 2008, 6, 234-7.	2.3	24
83	Daily activities: exploring their spectrum and prognostic impact in older, chemotherapy-treated lung cancer patients. Supportive Care in Cancer, 2003, 11, 460-464.	1.0	23
84	Incorporating Biomarkers of Frailty and Senescence in Cancer Therapeutic Trials. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 722-728.	1.7	23
85	Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markersâ€. European Journal of Cardio-thoracic Surgery, 2018, 53, 1214-1222.	0.6	23
86	Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. Oncotarget, 2015, 6, 35737-35754.	0.8	23
87	The Role of Systemic Inflammation in Cancer-Associated Muscle Wasting and Rationale for Exercise as a Therapeutic Intervention. JCSM Clinical Reports, 2018, 3, .	0.5	23
88	A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Medical Oncology, 2012, 29, 1005-1009.	1.2	22
89	Seizures in patients with primary brain tumors: what is their psychosocial impact?. Journal of Neuro-Oncology, 2016, 128, 285-291.	1.4	22
90	Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance) Tj ETQqC 24, 617-623.	0 0 0 rgBT 1.9	/Overlock 10 T 22

24, 617-623.

#	Article	IF	CITATIONS
91	Exploring Vitamin and Mineral Supplementation and Purported Clinical Effects in Patients With Small Cell Lung Cancer: Results From the Mayo Clinic Lung Cancer Cohort. Nutrition and Cancer, 2005, 51, 7-12.	0.9	21
92	Phase II Study of Preoperative Pemetrexed, Carboplatin, and Radiation Followed by Surgery for Locally Advanced Esophageal Cancer and Gastroesophageal Junction Tumors. Journal of Thoracic Oncology, 2010, 5, 1994-1998.	0.5	21
93	Cancer Patients and Their Companion Animals: Results from a 309-Patient Survey on Pet-Related Concerns and Anxieties During Chemotherapy. Journal of Cancer Education, 2010, 25, 396-400.	0.6	21
94	Marital Status and Quality of Life in Patients with Esophageal Cancer or Barrett's Esophagus: The Mayo Clinic Esophageal Adenocarcinoma and Barrett's Esophagus Registry Study. Digestive Diseases and Sciences, 2010, 55, 2860-2868.	1.1	21
95	The impact of a spiritual legacy intervention in patients with brain cancers and other neurologic illnesses and their support persons. Psycho-Oncology, 2017, 26, 346-353.	1.0	21
96	Do patients with schizophrenia receive stateâ€ofâ€theâ€art lung cancer therapy? A brief report. Psycho-Oncology, 2008, 17, 721-725.	1.0	20
97	Are Cancer Survivors/Patients Knowledgeable About Osteoporosis? Results from a Survey of 285 Chemotherapy-treated Cancer Patients and Their Companions. Journal of Nutrition Education and Behavior, 2008, 40, 144-148.	0.3	20
98	Oral Cancer Chemotherapy Adherence and Adherence Assessment Tools: a Report from North Central Cancer Group Trial N0747 and a Systematic Review of the Literature. Journal of Cancer Education, 2013, 28, 770-776.	0.6	20
99	Malignant Bowel Obstruction in Patients With Recurrent Ovarian Cancer. American Journal of Hospice and Palliative Medicine, 2016, 33, 272-275.	0.8	20
100	Overcoming obstacles in the design of cancer anorexia/weight loss trials. Critical Reviews in Oncology/Hematology, 2017, 117, 30-37.	2.0	20
101	Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non–Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711). Journal of Thoracic Oncology, 2018, 13, 996-1003.	0.5	20
102	Folate status among patients with non-small cell lung cancer: A case-control study. Journal of Surgical Oncology, 2001, 77, 247-252.	0.8	19
103	Impact of Socioeconomic Status on Pretreatment Weight Loss and Survival in Non–Small-Cell Lung Cancer. Journal of Oncology Practice, 2018, 14, e211-e220.	2.5	19
104	Adverse Event Burden Scoreâ€"A Versatile Summary Measure for Cancer Clinical Trials. Cancers, 2020, 12, 3251.	1.7	19
105	Esophageal cancer and the esophagus: Challenges and potential strategies for selective cytoprotection of the tumor-bearing organ during cancer treatment. Seminars in Radiation Oncology, 2002, 12, 62-67.	1.0	18
106	Social support and its implications in older, earlyâ€stage breast cancer patients in CALGB 49907 (Alliance) Tj E	ГQq <u>Q,8</u> 0 г <u>ғ</u>	gBT <sub>18</sub> Overlock
107	Rash from EGFR inhibitors: Opportunities and challenges for palliation. Current Oncology Reports, 2008, 10, 304-308.	1.8	17
108	Bevacizumab-induced nasal septal perforation: Incidence of symptomatic, confirmed event(s) in colorectal cancer patients. Acta $Oncol\tilde{A}^3$ gica, $2011$ , $50$ , $578-581$ .	0.8	17

#	Article	IF	CITATIONS
109	A Pilot Study of Long-Acting Octreotide for Symptomatic Malignant Ascites. Oncology, 2012, 82, 315-320.	0.9	17
110	Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993). Supportive Care in Cancer, 2012, 20, 1729-1735.	1.0	17
111	The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436). Journal of Geriatric Oncology, 2018, 9, 228-234.	0.5	17
112	A Multicenter Comparison of Complementary and Alternative Medicine (CAM) Discussions in Oncology Care: The Role of Time, Patient-Centeredness, and Practice Context. Oncologist, 2019, 24, e1180-e1189.	1.9	17
113	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Pancreatology, 2020, 20, 101-109.	0.5	17
114	Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1501-1508.	2.9	17
115	The Management of Cancer Symptoms and Treatment-Induced Side Effects With Cannabis or Cannabinoids. Journal of the National Cancer Institute Monographs, 2021, 2021, 86-98.	0.9	17
116	An Update on Advance Directives in the Medical Record: Findings from 1186 Consecutive Patients with Unresectable Exocrine Pancreas Cancer. Journal of Gastrointestinal Cancer, 2008, 39, 100-103.	0.6	16
117	The cancer anorexia/weight loss syndrome: exploring associations with single nucleotide polymorphisms (SNPs) of inflammatory cytokines in patients with non-small cell lung cancer. Supportive Care in Cancer, 2010, 18, 1299-1304.	1.0	16
118	Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Research and Treatment, 2017, 163, 391-398.	1.1	16
119	Perspectives on the Medical, Quality of Life, and Economic Consequences of Hiccups. Current Oncology Reports, 2019, 21, 113.	1.8	16
120	Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer. Gynecologic Oncology, 2020, 158, 646-652.	0.6	16
121	Role of dietary carbohydrates on risk of lung cancer. Lung Cancer, 2021, 155, 87-93.	0.9	16
122	Developing an Educational Intervention to Address Financial Hardship in Cancer Patients. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 424-433.	1.2	15
123	Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial. Supportive Care in Cancer, 2004, 12, 640-4.	1.0	14
124	Risk-adjusted outcomes in elderly endometrial cancer patients: Implications of the contrasting impact of age on progression-free and cause-specific survival. Gynecologic Oncology, 2015, 138, 133-140.	0.6	14
125	"Ultimately, mom has the call― Viewing clinical trial decision making among patients with ovarian cancer through the lens of relational autonomy. Health Expectations, 2018, 21, 981-989.	1.1	14
126	The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). Journal of Geriatric Oncology, 2018, 9, 221-227.	0.5	14

#	Article	IF	CITATIONS
127	Methylarginine metabolites are associated with attenuated muscle protein synthesis in cancer-associated muscle wasting. Journal of Biological Chemistry, 2020, 295, 17441-17459.	1.6	14
128	Electronic Geriatric Assessment: Is It Feasible in a Multi-Institutional Study That Included a Notable Proportion of Older African American Patients? (Alliance A171603). JCO Clinical Cancer Informatics, 2021, 5, 435-441.	1.0	14
129	An update: cancer-associated anorexia as a treatment target. Current Opinion in Clinical Nutrition and Metabolic Care, 2001, 4, 179-182.	1.3	13
130	Skeletal muscle mitochondrial dysfunction and muscle and whole body functional deficits in cancer patients with weight loss. Journal of Applied Physiology, 2022, 132, 388-401.	1.2	13
131	Comparative Efficacy of Dronabinol and Megestrol Acetate. Journal of Clinical Oncology, 2002, 20, 2912-2913.	0.8	12
132	Shopping for nutrition-based complementary and alternative medicine on the internet: How much money might cancer patients be spending online?. Journal of Cancer Education, 2007, 22, 174-176.	0.6	12
133	The wastingâ€associated metabolite succinate disrupts myogenesis and impairs skeletal muscle regeneration. JCSM Rapid Communications, 2020, 3, 56-69.	0.6	12
134	Fish oil, lean tissue, and cancer: is there a role for eicosapentaenoic acid in treating the cancer anorexia/weight loss syndrome?. Critical Reviews in Oncology/Hematology, 2005, 55, 37-43.	2.0	11
135	Cumulative Morbidity and Late Mortality in Long-Term Survivors of Exocrine Pancreas Cancer. Journal of Gastrointestinal Cancer, 2009, 40, 46-50.	0.6	11
136	A qualitative study of the ramifications of rash from epidermal growth factor receptor (EGFR) inhibitors. Psycho-Oncology, 2011, 20, 1246-1249.	1.0	11
137	Adjuvant Chemotherapy in Colon Cancer: Ageism or Appropriate Care?. Journal of Clinical Oncology, 2011, 29, 3209-3210.	0.8	11
138	Who is Counseled to Lose Weight? Survey Results and Anthropometric Data from 3,149 Lower Socioeconomic Women. Journal of Community Health, 2012, 37, 202-207.	1.9	11
139	Genetically Predicted Telomere Length is not Associated with Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 971-974.	1.1	11
140	Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302). Breast Cancer Research and Treatment, 2017, 166, 793-808.	1.1	11
141	Patient and family member perspectives on searching for cancer clinical trials: A qualitative interview study. Patient Education and Counseling, 2017, 100, 349-354.	1.0	11
142	Cancer in Transgender Patients: One Case in 385,820 ls Indicative of a Paucity of Data. Journal of Oncology Practice, 2018, 14, 270-272.	2.5	11
143	What occurs in the other 20% of cancer patients with chemotherapy-induced nausea and vomiting (CINV)? A single-institution qualitative study. Supportive Care in Cancer, 2019, 27, 249-255.	1.0	11
144	Pharmacologic therapy for the cancer anorexia/weight loss syndrome: A data-driven, practical approach. The Journal of Supportive Oncology, 2006, 4, 499-502.	2.3	11

#	Article	IF	CITATIONS
145	Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash: A Consecutive Patient Series that Illustrates the Need for Rigorous Palliative Trials. Journal of Palliative Medicine, 2011, 14, 153-156.	0.6	10
146	Nasal Septal Perforation from Bevacizumab: A Discussion of Outcomes, Management, and Pharmacovigilance. Current Oncology Reports, 2012, 14, 307-310.	1.8	10
147	Pemetrexed for Ovarian Cancer: A Systematic Review of the Published Literature and a Consecutive Series of Patients Treated in a Nonclinical Trial Setting. Case Reports in Oncology, 2014, 7, 541-549.	0.3	10
148	Incidence, Characteristics, and Implications of Seizures in Patients With Glioblastoma. American Journal of Hospice and Palliative Medicine, 2017, 34, 650-653.	0.8	10
149	Oral cinacalcet responsiveness in non-parathyroid hormone mediated hypercalcemia of malignancy. Medical Hypotheses, 2020, 143, 110149.	0.8	10
150	Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma. The Journal of Supportive Oncology, 2007, 5, 41-6.	2.3	10
151	Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival. BMC Cancer, 2015, 15, 711.	1.1	9
152	Clinical and Emergent Biomarkers and Their Relationship to the Prognosis of Ovarian Cancer. Oncology, 2016, 90, 59-68.	0.9	9
153	l'm Still Me: Inspiration and Instruction from Individuals with Brain Cancer. Journal of Health Care Chaplaincy, 2017, 23, 15-33.	0.7	9
154	Advanced ovarian cancer patients identify opportunities for prehabilitation: A qualitative study. Gynecologic Oncology Reports, 2021, 36, 100731.	0.3	9
155	Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series. Blood Cancer Journal, 2022, 12, 11.	2.8	9
156	Results of a planned interim toxicity analysis with trimodality therapy, including carboplatin AUC = 4, paclitaxel, 5-fluorouracil, amifostine, and radiation for locally advanced esophageal cancer: preliminary analyses and treatment recommendations from the North Central Cancer Treatment Group. International Seminars in Surgical Oncology, 2004, 1, 9.	1.1	8
157	Patients' rationale for declining participation in a cancerâ€associated weight loss study. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 121-125.	2.9	8
158	Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated Patients. Journal of Palliative Medicine, 2018, 21, 1334-1338.	0.6	8
159	Teaching Health-Care Providers to Query Patients With Cancer About Sexual and Gender Minority (SGM) Status and Sexual Health. American Journal of Hospice and Palliative Medicine, 2019, 36, 533-537.	0.8	8
160	Patients' Perspectives and Advice on How to Discuss Sexual Orientation, Gender Identity, and Sexual Health in Oncology Clinics. American Journal of Hospice and Palliative Medicine, 2020, 37, 1053-1061.	0.8	8
161	Understanding Verbosity: Funding Source and the Length of Consent Forms for Cancer Clinical Trials. Journal of Cancer Education, 2021, 36, 1248-1252.	0.6	8
162	Frequency and Symptomatology of Hiccups in Patients With Cancer: Using an On-Line Medical Community to Better Understand the Patient Experience. American Journal of Hospice and Palliative Medicine, 2022, 39, 147-151.	0.8	8

#	Article	IF	CITATIONS
163	Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial Journal of Clinical Oncology, 2012, 30, 314-314.	0.8	8
164	A Chaplain-led Spiritual Life Review Pilot Study for Patients with Brain Cancers and Other Degenerative Neurologic Diseases. Rambam Maimonides Medical Journal, 2015, 6, e0015.	0.4	7
165	"Enjoy glass of wine before eating:―a randomized trial to test the orexigenic effects of this advice in advanced cancer patients. Supportive Care in Cancer, 2016, 24, 3739-3746.	1.0	7
166	A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome. Supportive Care in Cancer, 2017, 25, 833-838.	1.0	7
167	Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance) Tj ETQq1 1	0. <b>7&amp;\$</b> 314	rgBT /Overlo
168	Poly (ADP-Ribose) Polymerase Inhibition for Chemotherapy-Induced Peripheral Neuropathy: A Meta-Analysis of Placebo-Controlled Trials. Journal of Palliative Medicine, 2019, 22, 977-980.	0.6	7
169	Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice. PLoS ONE, 2019, 14, e0226440.	1.1	7
170	Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review. Current Oncology Reports, 2021, 23, 86.	1.8	7
171	Adenosine Triphosphate: Does It Help Cancer Patients "Get Bigger and Stronger�. Journal of Clinical Oncology, 2002, 20, 362-363.	0.8	6
172	Wine for Appetite Loss: "How Do You Know?― Journal of Clinical Oncology, 2007, 25, 1285-1287.	0.8	6
173	E-Mail and Photographs: A Case Report of a Patient-Initiated Diagnostic Tool in the Era of Electronic Communication. Journal of Palliative Medicine, 2010, 13, 335-337.	0.6	6
174	Parenteral Nutrition in Patients With Advanced Cancer: Merging Perspectives From the Patient and Healthcare Provider. Seminars in Oncology, 2011, 38, 439-442.	0.8	6
175	Comparative "nocebo effects†in older patients enrolled in cancer therapeutic trials: Observations from a 446â€patient cohort. Cancer, 2017, 123, 4193-4198.	2.0	6
176	Remarks on the design and analyses of longitudinal studies for cancer patients with anorexia and weight loss. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 1175-1182.	2.9	6
177	Querying Patients With Cancer About Sexual Health and Sexual and Gender Minority Status: A Qualitative Study of Health-Care Providers. American Journal of Hospice and Palliative Medicine, 2020, 37, 418-423.	0.8	6
178	Ωâ€3 Fatty Acid Supplements for Cancerâ€Associated Weight Loss. Nutrition in Clinical Practice, 2005, 20, 394-399.	1.1	5
179	Sunshine and Rash: Testing the Role of Sunscreen to Prevent Epidermal Growth Factor Receptor Inhibitor–Induced Rash. Supportive Cancer Therapy, 2007, 4, 198-202.	0.3	5
180	Parenteral nutrition in patients with cancer: recent guidelines and a need for further study. Current Opinion in Supportive and Palliative Care, 2010, 4, 272-275.	0.5	5

#	Article	IF	Citations
181	Anti-inflammatory therapy. Current Opinion in Supportive and Palliative Care, 2013, 7, 339-341.	0.5	5
182	Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?. Cancer Investigation, 2016, 34, 531-535.	0.6	5
183	Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). Journal of Geriatric Oncology, 2018, 9, 321-328.	0.5	5
184	Physician-Reported Experience and Understanding of Adverse Event Attribution in Cancer Clinical Trials. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 176-182.	1.2	5
185	Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology. Journal of Geriatric Oncology, 2020, 11, 179-183.	0.5	5
186	Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. Oncologist, 2020, 25, e1681-e1690.	1.9	5
187	Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer. Pancreatology, 2021, 21, 379-383.	0.5	5
188	Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729). Oncologist, 2021, 26, e435-e444.	1.9	5
189	Should Loss of Appetite Be Palliated in Patients with Advanced Cancer?. Current Treatment Options in Oncology, 2021, 22, 31.	1.3	5
190	Image-guided tumor ablation in gynecologic oncology: Review of interventional oncology techniques and case examples highlighting a collaborative, multidisciplinary program. Gynecologic Oncology, 2021, 160, 835-843.	0.6	5
191	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. Oncologist, 2021, 26, 610-618.	1.9	5
192	Toxicity and survival outcomes in older adults receiving concurrent or sequential chemoradiation for stage III non-small cell lung cancer in Alliance trials (Alliance A151812). Journal of Geriatric Oncology, 2021, 12, 563-571.	0.5	5
193	Targeting and Palliating Malignant Ascites: An Overview of an Upcoming Clinical Trial from the North Central Cancer Treatment Group. Supportive Cancer Therapy, 2005, 3, 59-62.	0.3	4
194	A Survey of Patient Advocates within the National Cancer Institute's Prostate Cancer SPORE Program: Who are They? What Motivates Them? What Might They Tell Us?. Journal of Cancer Education, 2008, 23, 222-225.	0.6	4
195	Side effects and pharmaceutical company bias: adverse event reporting in cancer supportive and palliative care trials. Expert Opinion on Investigational Drugs, 2008, 17, 1787-1790.	1.9	4
196	Capecitabine and Temozolomide: Design, Implementation, and Preliminary Outcomes From a Pilot Project to Ensure Safe Prescribing of Oral Chemotherapy. Journal of Oncology Practice, 2010, 6, 210-212.	2.5	4
197	Is Spanish Language a Barrier to Domestic Violence Assessment?. Journal of Women's Health, 2011, 20, 1111-1116.	1.5	4
198	Exploring Therapeutic Decisions in Elderly Patients with Non-Small Cell Lung Cancer: Results and Conclusions from North Central Cancer Treatment Group Study NO222. Cancer Investigation, 2011, 29, 266-271.	0.6	4

#	Article	IF	Citations
199	Former Military Officers from the Republic of Vietnam Now Living in the United States (US): Exploring their Perceptions of the US Healthcare System. Journal of Community Health, 2011, 36, 992-998.	1.9	4
200	Practical Strategies to Circumvent and/or Surmount Six Barriers in Health Disparities Research: Observations from a Pilot Project Among Vietnamese Americans. Journal of Cancer Education, 2011, 26, 243-247.	0.6	4
201	How Important is Palliative Care?. Current Oncology Reports, 2011, 13, 252-254.	1.8	4
202	Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715). Oncologist, 2019, 24, e284-e291.	1.9	4
203	Androgen Mediation—and Antiandrogens Mitigation—of the Epidermal Growth Factor Receptor (EGFR) Inhibitor–Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series. American Journal of Hospice and Palliative Medicine, 2019, 36, 519-525.	0.8	4
204	A qualitative study of healthcare-related experiences of non-smoking women with lung cancer. Supportive Care in Cancer, 2020, 28, 123-130.	1.0	4
205	Behavioral, psychological, and supportive care interventions in geriatric oncology: The Cancer and Aging Research Group infrastructure core. Journal of Geriatric Oncology, 2020, 11, 347-349.	0.5	4
206	Observations with alpelisib in older patients (≥ 65Âyear of age) with breast cancer in a non-clinical trial setting. Breast Cancer Research and Treatment, 2021, 188, 15-20.	1.1	4
207	Disparities in older adult accrual to cancer trials: Analysis from the alliance for clinical trials in oncology (A151736). Journal of Geriatric Oncology, 2022, 13, 20-26.	0.5	4
208	Alpelisib-induced hyperglycemia in older patients with breast Cancer: Qualitative findings. Journal of Geriatric Oncology, 2021, 12, 1114-1117.	0.5	4
209	Palliating hiccups in cancer patients: moving beyond recommendations from Leonard the lion. The Journal of Supportive Oncology, 2009, 7, 129-30.	2.3	4
210	Tumor Necrosis Factor–α as a Treatment Target for the Cancer Anorexia/Weight Loss Syndrome. Supportive Cancer Therapy, 2004, 1, 237-242.	0.3	3
211	New agents, new rashes: An update on skin complications from cancer chemotherapy. Current Oncology Reports, 2006, 8, 269-274.	1.8	3
212	Is age ≥70years an important predictor of adverse events among patients enrolled in metastatic melanoma trials? Findings from pooled analyses of therapeutic trials. Journal of Geriatric Oncology, 2012, 3, 307-311.	0.5	3
213	Ureteral obstruction in cancer patients: a qualitative study. Psycho-Oncology, 2016, 25, 605-609.	1.0	3
214	Self-reported verbal abuse in 1300+ older women within a private, tertiary women's health clinic. Archives of Gerontology and Geriatrics, 2016, 66, 62-65.	1.4	3
215	Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Research and Treatment, 2018, 171, 325-334.	1.1	3
216	Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer?. American Journal of Hospice and Palliative Medicine, 2019, 36, 72-75.	0.8	3

#	Article	IF	Citations
217	Comparative Age-Based Prospective Multi-Institutional Observations of 12,367 Patients Enrolled to the American College of Surgeons Oncology Group (ACOSOG) Z901101 Trials (Alliance). Annals of Surgical Oncology, 2019, 26, 4213-4221.	0.7	3
218	Metastatic or suspected metastatic cancer in patients 90 years of age or older: A single-institution, multi-site study. Journal of Geriatric Oncology, 2021, 12, 1220-1224.	0.5	3
219	How Did a Multi-Institutional Trial Show Feasibility of Electronic Data Capture in Older Patients With Cancer? Results From a Multi-Institutional Qualitative Study (Alliance A171902). JCO Clinical Cancer Informatics, 2021, 5, 442-449.	1.0	3
220	Randomized, Double-Blind Trial on the Impact of Word Count in Cancer Clinical Trial Consent Forms. JCO Oncology Practice, 2021, 17, e1460-e1472.	1.4	3
221	A Critical Look at the Role of Chemotherapy in Older Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 83-90.	0.5	3
222	Can older patients adopt and maintain a ketogenic diet? An observational study in support of clinical trials in older patients. Medicine (United States), 2021, 100, e28033.	0.4	3
223	Dexamethasone and hiccups: a 2000-patient, telephone-based study. BMJ Supportive and Palliative Care, 2023, 13, e790-e793.	0.8	3
224	Evaluating and palliating hiccups. BMJ Supportive and Palliative Care, 2022, 12, 475-478.	0.8	3
225	Aggressive multimodality therapy for patients with locally advanced esophageal cancer: is there a role for amifostine?. Seminars in Oncology, 2003, 30, 72-75.	0.8	2
226	Wantedâ€"and Neededâ€"More Studies in Geriatric Lung Cancer Patients. Journal of Thoracic Oncology, 2007, 2, 103-104.	0.5	2
227	If You Hold It Off-Hours, Will They Come? Results from a Feasibility Project Intended to Stimulate Interest in the Physician-Investigator Career Path Among Medical Oncology Trainees. Journal of Cancer Education, 2009, 24, 200-203.	0.6	2
228	Osseous metastases: drugs that enhance bone integrity and prevent adverse skeletal events. Expert Opinion on Pharmacotherapy, 2009, 10, 723-726.	0.9	2
229	Cancer chemotherapy: with or without food?. Supportive Care in Cancer, 2010, 18, 13-16.	1.0	2
230	STEPP for the EGFR Inhibitor–Induced Rash—Definitely a Step in the Right Direction. Current Oncology Reports, 2010, 12, 223-225.	1.8	2
231	Integrative and complementary medicine among cancer patients: At what price?. European Journal of Integrative Medicine, 2011, 3, e139-e141.	0.8	2
232	An overview of the European Society of Medical Oncology (ESMO) Symposium on Cancer and Nutrition 2009: from cancer prevention to nutrition support to alleviating suffering in patients with advanced cancer. Supportive Care in Cancer, 2011, 19, 1895-1898.	1.0	2
233	The Purported Effects of Alcohol on Appetite and Weight in Lung Cancer Patients. Nutrition and Cancer, 2011, 63, 1251-1255.	0.9	2
234	Adjuvant chemotherapy and targeted therapy in elderly non-small-cell lung cancer patients. Aging Health, 2012, 8, 309-316.	0.3	2

#	Article	IF	Citations
235	Incidence and Outcomes of Chemotherapy and Radiation in Morbidly Obese Patients with Locally Advanced Lung and Esophageal Cancers: A Single-Institution Experience. Cancer Control, 2014, 21, 63-66.	0.7	2
236	Nasal vestibulitis: an under-recognized and under-treated side effect of cancer treatment?. Supportive Care in Cancer, 2018, 26, 3909-3914.	1.0	2
237	How (and why) to ask the older cancer patient about sexual health and sexual minority status. Journal of Geriatric Oncology, 2020, 11, 576-578.	0.5	2
238	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precision Oncology, 2021, 5, 1228-1240.	1.5	2
239	Falls: descriptive rates and circumstances in age-unspecified patients with locally advanced esophageal cancer. Supportive Care in Cancer, 2021, 29, 733-739.	1.0	2
240	Shorter Treatment-Na $\tilde{A}$ -ve Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 210-216.	1.1	2
241	Establishing the Groundwork for Clinical Trials With Hiccupops $\langle \sup \rangle \hat{A}^{\otimes} \langle  \sup \rangle$ for Hiccup Palliation. American Journal of Hospice and Palliative Medicine, 2022, 39, 1210-1214.	0.8	2
242	In Their Own Words, "Waiting Sucks:―A Qualitative Study of Medical Testing-Related Anxiety in Patients with Cancer. American Journal of Hospice and Palliative Medicine, 2023, 40, 468-474.	0.8	2
243	Hiccups in patients with cancer: a multi-site, single-institution study of etiology, severity, complications, interventions, and outcomes. BMC Cancer, 2022, 22, .	1.1	2
244	Integrative nutritional approaches to loss of weight and appetite in patients with advanced cancer. European Journal of Integrative Medicine, 2011, 3, e233-e236.	0.8	1
245	Consumer Beware: A Systematic Assessment of Potential Bias in the Lay Electronic Media to Examine the Portrayal of "PARP―Inhibitors for Cancer Treatment. Journal of Cancer Education, 2011, 26, 474-477.	0.6	1
246	A Single-Institution Study of Demographics and Outcomes of Adult Patients with Multiple Cancers. Cancer Control, 2016, 23, 455-460.	0.7	1
247	Ovarian cancer patients' and their family members' perspectives on novel vaccine and virotherapy trials. Clinical Trials, 2016, 13, 660-664.	0.7	1
248	Cancer-associated weight loss: releasing its firm grip on negative clinical outcomes. Current Opinion in Supportive and Palliative Care, 2017, 11, 259-260.	0.5	1
249	Looking Back, Looking Forward: The Ethical Framing of Complementary and Alternative Medicine in Oncology Over the Last 20 Years. Oncologist, 2018, 23, 639-641.	1.9	1
250	Loratadine for Paclitaxel-Induced Myalgias and Arthralgias. American Journal of Hospice and Palliative Medicine, 2020, 37, 235-238.	0.8	1
251	Nanoliposomal irinotecan-based chemotherapy after regular irinotecan-based chemotherapy in patients with pancreas cancer Journal of Clinical Oncology, 2021, 39, 402-402.	0.8	1
252	Colorectal Cancer, Crohn-Like Lymphoid Reactions, Survival — And the Power of a Good Cup of Coffee!. Mayo Clinic Proceedings, 2022, 97, 15-17.	1.4	1

#	Article	IF	CITATIONS
253	Olaparib for ovarian cancer: a single-institution, multi-site qualitative study. Supportive Care in Cancer, 2022, , $1.$	1.0	1
254	A critical look at the role of chemotherapy in older patients with non-small cell lung cancer. Journal of Thoracic Oncology, 2007, 2, 83-90.	0.5	1
255	Understanding "Patient refuses―among 90+ year old patients with cancer or presumed cancer. Journal of Geriatric Oncology, 2022, , .	0.5	1
256	Does the cancer geriatric assessment (GA) introduce bias into clinical trials? Observations from 988 prospectively recruited patients. Journal of Geriatric Oncology, 2021, , .	0.5	1
257	Anorexia. American Journal of Cancer, 2002, 1, 269-275.	0.4	0
258	Does megestrol acetate down-regulate interleukin-6 in cancer-associated anorexia?. Supportive Care in Cancer, 2002, 10, 568-568.	1.0	0
259	Fat, fish oil and the cancer anorexia/weight loss syndrome. Evidence - Based Integrative Medicine, 2003, 1, 51-55.	0.2	0
260	Loss of appetite and weight., 2003,, 369-373.		0
261	An Update on Therapeutics: The Cancer Anorexia/Weight Loss Syndrome in Advanced Cancer Patients. , 2006, , 643-648.		0
262	Who should receive parenteral nutrition or pharmacologic therapy for loss of appetite and weight in the setting of incurable cancer?. Current Opinion in Supportive and Palliative Care, 2007, 1, 279-280.	0.5	0
263	A Critical Look at the Role of Chemotherapy in Older Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 83-90.	0.5	O
264	Bisphosphonates: Preventing skeletal morbidity and maybe doing more. Current Oncology Reports, 2009, 11, 251-252.	1.8	0
265	Nutritional support of critically ill cancer patients. , 0, , 147-154.		O
266	Non-small-cell lung cancer in the elderly with an emphasis on chemotherapy in the adjuvant and metastatic disease settings. Lung Cancer Management, 2014, 3, 411-416.	1.5	0
267	Should Vital Signs be Routinely Obtained Prior to Intravenous Chemotherapy? Results from a 2-Center Study. Cancer Control, 2015, 22, 515-519.	0.7	O
268	Nutrition Support in Solid Tumor Cancer Patients. , 2015, , 253-260.		0
269	Radiation-Refractory Brain Metastases in Patients with Non-Small Cell Lung Cancer. Journal of Palliative Medicine, 2015, 18, 707-710.	0.6	0
270	Response. Supportive Care in Cancer, 2015, 23, 2213-2213.	1.0	0

#	Article	IF	CITATIONS
271	Chemotherapy Acute Infusion Reactions: A Qualitative Report of the Perspectives of Patients With Cancer. American Journal of Hospice and Palliative Medicine, 2018, 35, 1384-1389.	0.8	O
272	Numbers Have Life: A Commentary on "Predictors of Survival in Patients with Advanced Gastrointestinal Malignancies Admitted to the Intensive Care Unit― Oncologist, 2019, 24, 433-434.	1.9	0
273	The Need to Prioritize and Re-prioritize Palliative Care Options: Smoking Cessation as a Case-in-Point. Current Treatment Options in Oncology, 2019, 20, 33.	1.3	0
274	Cancer Cachexia. , 2020, , 593-597.e1.		0
275	Non-Squamous, Non-Basal Cell Cancers of the Skin: Exploring Associations Between Site of Disease and Depression. American Journal of Hospice and Palliative Medicine, 2020, 38, 104990912096960.	0.8	0
276	Conversations on Cancer Chemotherapy Cessation in Patients With Advanced Cancer: Qualitative Findings From a Multi-Institutional Study. American Journal of Hospice and Palliative Medicine, 2021, 38, 175-179.	0.8	0
277	HER2-overexpression/amplification and survival in patients with resectable esophageal/gastroesophageal junction adenocarcinoma (E/GEJ-AC) treated with neoadjuvant carboplatin/paclitaxel-based chemoradiation Journal of Clinical Oncology, 2021, 39, 239-239.	0.8	0
278	Tumor Necrosis Factor Inhibitors in Cancer-Associated Weight Loss Syndrome., 2005,, 473-487.		0
279	Nutrition and Cancer. Nutrition and Disease Prevention, 2007, , 421-432.	0.1	0
280	Overview of the management of the anorexia/weight loss syndrome. , 2009, , 538-545.		0
281	Cancer Cachexia. , 2014, , 620-625.		0
282	Forty Years Fast Forward: Vietnamese Refugees in the United States with Comments on Their Cancer Care., 2016,, 417-425.		0
283	A Cautionary Tale: Grouping Patients on Late Events. Mayo Clinic Proceedings, 2022, 97, 449-453.	1.4	0
284	Why should we care about the cancer anorexia/weight loss syndrome?. Oncology, 2003, 17, 5-6.	0.4	0
285	Helping people cope with bereavement: an opportunity for health care providers to link Web-based resources across Minnesota. Minnesota Medicine, 2006, 89, 42-4.	0.1	0
286	In search of rigorous data on how to palliate the EGFR inhibitor-induced rash. Oncology, 2009, 23, 196, 198.	0.4	0
287	Reply to A. Rizzo et al. JCO Precision Oncology, 2022, 6, e2200061.	1.5	0
288	"lt's Like You Stuck a Pin in It:―African American/Black Patients Describe Cutaneous Toxicity From Epidermal Growth Factor Receptor Inhibitors. American Journal of Hospice and Palliative Medicine, 2022, , 104990912210926.	0.8	0

#	Article	IF	CITATIONS
289	Equity. Cancer, 2022, , .	2.0	O
290	Cancer anorexia/weight loss syndrome: clinical science. , 0, , 142-150.		0
291	Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice. , 2019, 14, e0226440.		O
292	Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice., 2019, 14, e0226440.		0
293	Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice. , 2019, 14, e0226440.		0
294	Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice. , 2019, 14, e0226440.		0
295	Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice. , 2019, 14, e0226440.		0
296	Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice. , 2019, 14, e0226440.		0
297	Esophageal Adenocarcinoma., 0,, 31-113.		0
298	Olanzapine for cisplatin-induced hiccups: observations from a 338-patient study. Annals of Palliative Medicine, 2021, .	0.5	0
299	Succinct Cancer Clinical Trial Consent Forms in Rural Patients With Cancer: A Secondary Analysis of a Randomized, Double-Blinded study. Journal of Patient Experience, 2022, 9, 237437352211072.	0.4	0
300	Analysis of patient (pt) withdrawal of consent using 11,993 pts from 58 alliance for clinical trials in oncology trials Journal of Clinical Oncology, 2022, 40, 6513-6513.	0.8	0